TGTX · TG Therapeutics, Inc.
$54.17
+1.90% last session
End-of-day data · close of 2026-10-23
Market cap
$8B
Enterprise value
$8B
Trailing P/E
19.7
Forward P/E
20.0
Dividend yield
0.0%
Beta
1.80
Avg volume
2M
Employees
0K
Daily Change %
1.90%
5 Days Change
-1.50%
10 Days Change
-2.17%
30 Days Change
-5.07%
60 Days Change
-5.09%
Month to Day Change
-0.86%
Year to Day Change
78.33%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TGTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-01
Latest call per bank · past 12 months
JP Morgan
Overweight$72.00
+32.9% vs priceBank of America
Underperform$20.00
-63.1% vs priceGoldman Sachs
Neutral$39.00
-28.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-01 | HC Wainwright & Co. | Reiterates | Buy | $78.00 |
| 2026-08-07 | JP Morgan | Maintains | Overweight | $65.00 → $72.00 |
| 2026-07-27 | B. Riley Securities | Maintains | Buy | $55.00 → $86.00 |
| 2026-07-13 | HC Wainwright & Co. | Maintains | Buy | $70.00 → $77.00 |
| 2026-07-07 | Bank of America | Maintains | Underperform | $17.00 → $20.00 |
| 2026-07-06 | HC Wainwright & Co. | Reiterates | Buy | $70.00 |
| 2026-05-27 | HC Wainwright & Co. | Reiterates | Buy | $70.00 |
| 2026-05-06 | HC Wainwright & Co. | Maintains | Buy | $60.00 → $70.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 0.8% below the 50-day MA ($54.58).
- bullish: Price vs 200-day MA: Trading 25.7% above the 200-day MA ($43.09).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.11) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($26.94) and high ($59.06).
TGTX Price Chart
Loading chart for TGTX…
Fundamentals
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.